HOME > BUSINESS
BUSINESS
- Eisai CEO Says Aducanumab Resurrection Was a Surprise, Touts Totality of Data as He Relays New Findings
October 31, 2019
- Taisho’s Prescription Drug Sales Suffer Double-Digit Decline in H1, due to Capital Tie-Up Dissolution with Toyama Chemical
October 31, 2019
- Taisho, Novartis to Stop Comarketing Lusefi at December-End
October 31, 2019
- Roche Going Beyond Oncology to Rev Up Precision Medicine Drive in Ophthalmology, Neuroscience
October 30, 2019
- AstraZeneca’s Japan R&D Chief Tapped as Medical Affairs SVP for Global Oncology Biz
October 30, 2019
- Nesp Biosame Soon to Leapfrog Originator as 5.6 Billion Yen Logged in Just 2 Months
October 30, 2019
- Nichi-Iko to Succeed 2 Off-Patent Brands from Astellas
October 30, 2019
- Debiopharm on Hunt for Japanese Ally for 1st-in-Class Cancer Drug, Eyes PIII Launch in 2020
October 29, 2019
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
- Desalex Resupply Scheduled from Nov. 18: Kyorin
October 29, 2019
- Astellas’ Kidney Injury Med Gets FDA’s Fast Track Status
October 29, 2019
- AbbVie Embarking on Work Style Reform for Sales Reps, Lets Staffers Pick Locations
October 28, 2019
- With European OK, Astellas’ Xospata Extends Lead over Daiichi Sankyo’s FLT3 Rival
October 28, 2019
- Mitsubishi Tanabe Ups H1 Earnings Forecast
October 28, 2019
- Nichi-Iko to Gradually Resume Cefazolin Supply from Nov. 25
October 28, 2019
- General Phenotypes of Psychiatric Disorders Observed in iPS Cell Research: Sumitomo Dainippon, Keio Univ., Nagoya Univ.
October 25, 2019
- Chugai Notches Up Record Earnings in January-September on Hemlibra, Mainstays
October 25, 2019
- Shionogi to Focus on Safety, Not Sales, in Detailing Xofluza
October 25, 2019
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- Takeda Bags Worldwide Rights for Cour's Celiac Disease Treatment
October 24, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
